Aurobindo Pharma Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Aurobindo Pharma is transferring its domestic branded generic business to Auropharm for ₹143.21 crore. The company also announced a ₹800 crore buyback at a premium and positive Phase 3 results for its biosimilar product.

Aurobindo Pharma Announces Buyback and Positive Trial Results - 06 Apr, 2026

Aurobindo Pharma is experiencing a bullish trend with recommendations to buy at ₹1,314. Additionally, the company plans to acquire 26% of Swarnaakshu Solar by June 30.

Aurobindo Pharma's Bullish Outlook and Solar Acquisition - 30 Mar, 2026

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has partnered with STADA Arzneimittel AG to market biosimilars in Europe. The stock shows bullish momentum with a breakout indicating potential trend reversal.

Aurobindo Pharma Subsidiary Partners for Biosimilars - 27 Mar, 2026

Aurobindo Pharma's stock reached a 52-week high, supported by technical bullish signals and a strategic partnership for biosimilars in Europe. UBS upgraded its target price, reflecting positive market sentiment.

Aurobindo Pharma Achieves Milestones with Stock Surge - 25 Mar, 2026

Aurobindo Pharma is receiving bullish recommendations from multiple analysts, with target prices ranging from Rs 1,350 to Rs 1,610, driven by acquisitions and operational efficiencies.

Aurobindo Pharma Receives Strong Buy Recommendations - 24 Mar, 2026

Aurobindo Pharma is recommended as a buy due to a strong product pipeline and recent breakout, with a target price of ₹1,400 in 2-3 months.

Aurobindo Pharma Shows Strong Potential for Growth - 23 Mar, 2026

Aurobindo Pharma's subsidiary, Apitoria Pharma, received a Voluntary Action Indicated classification from the USFDA for its Unit-V facility, leading to a 3% rise in shares.

Aurobindo Pharma Secures VAI Classification, Shares Rise - 20 Mar, 2026

Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, received an OAI classification from the FDA following an inspection that revealed nine observations. The company does not foresee immediate business impact.

FDA Flags Aurobindo Pharma's Eugia Unit Inspection - 17 Mar, 2026

Aurobindo Pharma has achieved a decisive breakout, supported by strong technical indicators. Analysts recommend buying in the ₹1,300–₹1,280 range, targeting ₹1,390.

Aurobindo Pharma Breaks Out with Bullish Momentum - 16 Mar, 2026

Aurobindo Pharma announced that its Unit-IV has received a Voluntary Action Indicated (VAI) classification from the USFDA, marking the closure of a recent inspection.

Aurobindo Pharma's Unit Receives USFDA VAI Classification - 12 Mar, 2026

Aurobindo Pharma Ltd has shown significant bullish momentum, breaking out from consolidation with targets around ₹1,375. The stock has risen 2.08% today and 13.37% over the past month.

Aurobindo Pharma Shows Strong Bullish Momentum - 11 Mar, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Netprofit is up for the last 3 quarters, 824.75 Cr → 910.29 Cr (in ₹), with an average increase of 4.8% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Retail Investor have increased holdings from 6.38% to 6.55% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Up

In the last 1 month, AUROPHARMA stock has moved up by 8.3%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Mutual Funds have increased holdings from 19.30% to 19.52% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Revenue is up for the last 3 quarters, 7.97K Cr → 8.83K Cr (in ₹), with an average increase of 5.0% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

In the last 1 year, Torrent Pharmaceuticals Ltd has given 23.3% return, outperforming this stock by 1.4%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

In the last 3 years, Lupin Ltd has given 242.5% return, outperforming this stock by 93.3%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Promoters holdings remained unchanged at 51.82% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Foreign Institutions have decreased holdings from 14.21% to 13.94% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Nifty Midcap 100

BSE Healthcare

Nifty LargeMidcap 250

S&P BSE MidCap Select

NIFTY PHARMA

Nifty Midcap 50

S&P BSE 150 MidCap

BSE 500

Nifty Midcap 150

Nifty MidSmallcap 400

Nifty Midcap Sel

Nifty Healthcare

Nifty 500

Nifty 200

S&P BSE 250 LargeMidCap

S&P BSE 400 MidSmallCap

BSE 200

HDFC Mid Cap Fund -Direct Plan - Growth Option

Quant ELSS Tax Saver Growth Option Direct Plan

Quant Mid Cap Fund Growth Option Direct Plan

SBI Large & Midcap Fund Direct Growth

Quant Multi Cap Fund Growth Option Direct Plan

Aurobindo Pharma Ltd’s net profit jumped 7.62% since last year same period to ₹910.29Cr in the Q3 2025-2026. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 7.29% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-0.08	Bearish
CCI (20)	-63.97	Neutral
RSI (14)	52.07	Neutral
Momentum (10)	0.5	Bullish
ADI (14)	25.02	Bearish
Ultimate Oscillator (7,14,28)	55.78	Neutral

Name	Value	Action
SMA (20)	1340.26	Bearish
EMA (20)	1339.69	Bullish
VWMA (20)	1339.6	Bullish
SMA (50)	1339.04	Bullish
EMA (50)	1339.36	Bullish
SMA (200)	1335.54	Bullish
EMA (200)	1336.38	Bullish
KAMA (200)	1338.28	Bullish
DEMA (200)	1340.05	Bearish

Aurobindo Pharma Ltd (AUROPHARMA)

Summary

Overall

Oscillators

Moving Averages